Io­vance's $211M of­fer­ing; Almi­rall li­cens­es No­vo drug; As­traZeneca files Da­to-DXd; Sonata lay­offs

Plus oth­er news you may have missed from the FTC, Ever­est, Gilead, IsomAb, Oramed, In­novent, Sonata, Lari­mar and Im­munome.

Io­vance Bio­ther­a­peu­tics of­fers $211M in shares: The com­pa­ny is sell­ing more than 23 mil­lion shares for $9.15 each with the of­fer­ing ex­pect­ed to close on Feb­ru­ary 22. The cash should sup­port the launch of Io­vance’s T cell ther­a­py Am­tagvi, which was ap­proved Fri­day, and late-stage stud­ies of its pipeline drugs. — Ay­isha Shar­ma 

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.